Thromb Haemost 2016; 115(06): 1240-1248
DOI: 10.1160/TH15-09-0756
DOI: 10.1160/TH15-09-0756
Trial Protocol Design Paper
The MARINER trial[*] of rivaroxaban after hospital discharge for medical patients at high risk of VTE
Design, rationale, and clinical implicationsGary E. Raskob
1
University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma
City, Oklahoma, USA
,
Alex C. Spyropoulos
2
Anticoagulation and Clinical Thrombosis Services North Shore–LlJ Health System, Hofstra
North Shore-LIJ School of Medicine, Manhasset, New York, USA
,
Julie Zrubek
3
Janssen Research & Development, LLC, Raritan, New Jersey, USA
,
Walter Ageno
4
Department of Clinical and Experimental Medicine, University of Insubria, Varese,
Italy
,
Gregory Albers
5
Stanford Stroke Center, Department of Neurology and Neurological Sciences, Stanford
University, Stanford, California, USA
,
C. Gregory Elliott
6
Department of Medicine, Intermountain Medical Center and the University of Utah, Murray,
Utah, USA
,
Jonathan Halperin
7
Icahn School of Medicine at Mount Sinai, New York, New York, USA
,
Lloyd Haskell
3
Janssen Research & Development, LLC, Raritan, New Jersey, USA
,
William R. Hiatt
8
Division of Cardiology, University of Colorado School of Medicine and CPC Clinical
Research, Aurora, Colorado, USA
,
Gregory A. Maynard
9
University of California Davis Medical Center, Sacramento, California, USA
,
Gary Peters
3
Janssen Research & Development, LLC, Raritan, New Jersey, USA
,
Theodore Spiro
10
Bayer HealthCare Pharmaceuticals Inc, Whippany, New Jersey, USA
,
Philippe Gabriel Steg
11
Université Paris-Diderot, Sorbonne Paris-Cité, Paris, France
,
Eun Young Suh
3
Janssen Research & Development, LLC, Raritan, New Jersey, USA
,
Jeffrey I. Weitz
12
McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton,
Ontario, Canada
› Institutsangaben